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Background: Cardiovascular diseases (CVD) are among leading causes of death worldwide and amongst 
CVD, coronary artery disease (CAD) accounts for almost half of all cardiovascular deaths as the most 
common cause of death in the developed world. Vitamin D and the vitamin D-binding protein (VDBP) have 
been studied as possible CAD pathogenesis factors but literature data provide opposing evidence on their 
role in CAD. Herein we aimed to present novel evidence on the association of two VDBP polymorphisms 
(rs4588) and (rs7041) with CAD in patients after acute myocardial infarction and study possible correlations 
of these polymorphisms with 25-hydroxyvitamin D [25(OH)D] serum levels.
Methods: The cross-section genotyping study included 155 subjects with CAD upon acute myocardial 
infarct and 104 control subjects. All patients and control group were Caucasians of European descent. VDBP 
polymorphisms (rs4588) and (rs7041) were studied by use of RT-PCR. Liquid chromatography, tandem mass 
spectrometry (LC-MS/MS) method was used for measurement of vitamin D in the serum.
Results: Association of the VDBP (rs4588) T/T genotype with CAD patients after acute MI and 
correlation of VDBP (rs4588) genotype G/G with higher levels of total vitamin D were found. No 
correlation of 25(OH)D serum levels with CAD were established but the multivariate logistic regression 
modelling enabled association of total vitamin D level and VDBP (rs4588) T/T genotype with CAD and 
anteroseptal myocardial infarction (ASMI) CAD occurrence.
Conclusions: Obtained data speak in favor to the VDBP (rs4588) T/T genotype as a susceptibility factor 
for anteroseptal myocardial infarction where the same genotype showed to be generally more prevalent in 
smokers.
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Introduction
According to the World Health Organization (WHO), 
cardiovascular diseases (CVD) are among leading causes of 
death worldwide and account for 31% of all global deaths 
and 47% of all deaths at the European level (1). Elevated 
blood pressure, smoking, diabetes and hyperlipidemia 
still remain the main risk factors for development of 
the coronary heart disease, while physical inactivity, 
obesity, poor nutrition and low socio-economic status are 
considered to be the predisposing factors. Many other 
factors show correlation with coronary disease including 
proinflammatory factors and individual genetics (2-5). 
French, Italians, Irish (Northern), Albanians and Indians 
in their scientific literature point out national paradoxes 
deviating from the known pathogenesis of the development 
of CVDs and correlations with the known risk factors; 
hence it is understandable that the etiology of occurrence of 
coronary disease has not been sufficiently researched and it 
is still a subject of intense investigations (6).
Amongst CVD, coronary artery disease (CAD), 
is denoted as a pathologic process that affects coronary 
arteries (7). Including acute myocardium infarct (MI), it 
accounts for almost half of all cardiovascular deaths as the 
most common cause of death in the developed world (8). 
The large panel of predisposing factors still fail to explain 
the complex pathogenesis of CAD on the molecular level. 
Recently, a rather old concept on the role of inflammation 
as a driving mechanism of systemic changes leading to 
CAD, has been substantiated by a growing body of novel 
evidence (9). For example, a high degree of correlation in 
key inflammatory genes was recently found between subjects 
with CAD and the metabolic syndrome, which is not 
surprising knowing that diet and lifestyle heavily underlie 
CAD pathogenesis (10). The importance of immune 
processes in CAD is also underpinned by a well-studied 
role of innate immunity in the atherogenesis formation of 
the vessel lesions, their progression and ultimate clinical 
presentation (11). From this angle, growing research on 
vitamin D role in the innate immune response, and as 
such a possible predisposing factor for CVD, has been 
conducted (12). There are two main forms of vitamin 
D that  can be consumed from food,  v i tamin D3 
(cholecalciferol) and vitamin D2 (ergocalciferol). Vitamin 
D3 is also synthesized in the skin by conversion of 
7-dihydroxy-cholesterol via exposure to UV-B rays (13). 
Both vitamins D2 and D3 are hydroxylated in the liver 
into steroid hormones 25-hydroxyvitamin D2 and D3 
[25(OH)D] that are consequently 1-alpha-hydroxylated 
into the active vitamin D form 1,25-dihydroxy vitamin 
D2 and D3 [1,25(OH)D], mainly in the kidneys with 
parathyroid hormone (PTH) mediation. 1,25(OH)D binds 
to the ubiquitous vitamin D nuclear receptors (VDR) and 
influences transcription of a large number of vitamin D 
target genes. This whole metabolic pathway has a pivotal 
systemic role, e.g., it is essential for calcium homeostasis, 
healthy growth and remodeling of bone, neuromuscular and 
immune functions, as well as in reduction of inflammation 
and antioxidant processes. It is not therefore, surprising that 
low circulating 25(OH)D levels were found to correlate with 
general morbidity and mortality (14,15), or are associated 
with CVD (16,17) or CAD (18). Still, supplementation 
with vitamin D in CVD patients in controlled clinical 
trials did not prove effective as expected which hampers 
establishing of a direct link between 25(OH)D serum levels 
with CVD occurrence or outcome (19). The missing link 
may be in the genetic background as a number of papers 
report on specific genetic features that account for major 
differences in response to vitamin D supplementation or 
for differences in the 25(OH)D serum levels between races 
or populations (20,21). In this context, vitamin D-binding 
protein (VDBP) gene gained particular interest due to 
its importance in vitamin D metabolism and transport in 
the body. It is a highly polymorphic gene mapped on the 
chromosome 4 (22) and synthesized in the liver as the 
main carrier of vitamin D metabolites in the body, namely 
25(OH)D and 1,25-dihydroxyvitamin D. Biological effects 
of vitamin D on target cells may be also affected by genetic 
features of the VDBP gene (23). Some authors showed that 
genetic differences in VDBP gene cannot independently 
predict the prevalence and extent of CAD (24) while 
some showed association of the VDBP polymorphisms 
Thr420Lys (rs4588) and Asp416Glu (rs7041) with 
CAD (25). As literature data is still not conclusive on the 
VDBP polymorphisms role in CAD, our objective was to 
provide additional evidence on the association of VDBP 
polymorphisms (rs4588) and (rs7041) with CAD in patients 
after acute MI and to study possible correlations of these 
polymorphisms with 25(OH)D serum levels. 
Methods 
Patients and samples
The cross-section genotyping study included 155 subjects 
with CAD upon acute myocardial infarction (MI) and 
104 control subjects (Table 1) at Thalassotherapia Opatija, 
Clinic for rehabilitation, treatment, and prevention 
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of diseases of the heart and blood vessels, Croatia. All 
patients and control group were Caucasians of European 
descent from the population of the Primorsko Goranska-
County (Croatia). The patients within the CAD group 
have a medical history with the diagnosis of arterial 
hypertension (AH) (Table S1) and are under prescribed 
therapy. Lower mean blood pressure value is therefore 
due to adequate antihypertensive therapy. The test group 
consisted of patients undergoing stationary cardiologic 
rehabilitation program at Thalassotherapia Opatija 
after acute MI. In the control group higher mean blood 
pressure value was calculated than in the CAD group, but 
the value is still below the cut-off value for AH diagnosis 
(<140/90 mmHg). All patients were subjected to peracute 
coronary revascularization. The control group comprised 
healthy subjects of adequate age and gender, undergoing 
routine systematic examination. The research was approved 
by the Ethics Committee of Thalassotherapia Opatija and 
the Committee for Ethical Issues of the Faculty of Medicine 
of the University of Rijeka, Croatia. Data on age and sex, 
early illnesses and data on risk factors and habits (smoking, 
AH, diabetes, family anamnesis) were collected for all 
subjects (Table S1). The type of acute MI was determined 
by the electrocardiographic features (the acute MI with 
or without the elevation of ST segment), coronarography 
findings and invasive therapy. The excluding criteria for the 
study were: proven existence of malignant disease, kidney 
failure, primary hyperparathyroidism and substitute therapy 
for calcium and vitamin D. All subjects signed the informed 
consent pursuant to the Helsinki Declaration, approved by 
the Ethics Committee of Thalassotherapia Opatija and the 
Committee for Ethical Issues of the Faculty of Medicine. 
Detailed procedures used for clinical evaluation of patients 
are described in Supplemental file 1.
Genomic DNA extraction and genetic analysis
Genomic DNA was extracted from 200 µL peripheral 
blood using QIAamp DNA Blood Mini Kit (Qiagen, 
Hilden, Germany), on a QIAcube robotic workstation 
(Qiagen), according to the manufacturer’s manual. 
DNA quality and concentration were measured using a 
BioDrop spectrophotometer. Genotyping of VDBP gene 
polymorphisms (rs4588) and (rs7041) was performed 
with TaqMan Pre-designed SNP Genotyping Assay on 
an Applied Biosystems 7500 fast real-time PCR machine 
according to manufactures recommendation. The PCR 
cycling conditions were 95 ℃ for 10 min, followed by 45 
cycles of denaturation at 95 ℃ for 15 s and annealing/
extension at 60 ℃ for 1 minute. Collected results were 
analyzed with allelic discrimination analysis software 
available on Applied Biosystems 7500 fast PCR instrument. 
Vitamin D serum levels measurement
Serum samples (after an overnight fasting) were collected 
for 118 CAD patients after MI and 70 control subjects 
and stored at −80 ℃. Levels of 25(OH)D2 and 25(OH)D3 
were measured by use of the ACQUITY UPLC I-Class 
and Xevo TQD (Milford, Massachusetts, USA). For 
experiment creation and results analysis, MassLynx software 
(Waters, USA) was used, while the UPLC parameters 
were controlled through ACQUITY UPLC console. Solid 
phase extraction and liquid chromatography, tandem mass 
spectrometry (LC-MS/MS) procedures are described in the 
Supplemental file 1.
Statistics
Collected data were statistically evaluated using data 
analysis software system Dell Statistica, version 12. Dell Inc. 
(2015). Categorical variables are presented with frequencies 
or percentages and comparisons done using Pearson chi-
square (χ2) test. The association of categorical variables was 
expressed as odds ratio (OR) with a 95% confidence interval 
(CI). Normally distributed continuous variables (distribution 
Table 1 Age, body mass index (BMI) and blood pressure distribution between coronary artery disease (CAD) and control group
Variables All (N=259) CAD (N=155) Control (N=104) P value
Age, years 53±12 58±11 47±11 <0.001*
BMI, kg/m2 28.0±4.3 28.5±4.0 27.2±4.5 0.017*
Systolic blood pressure/mmHg 124±15 121±15 127±16 0.005*
Diastolic blood pressure/mmHg 78±10 78±10 78±9 0.887
Data are presented as mean ± SD. Statistical significance (t-test) is denoted with an asterisk (*). N, number of subjects.
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tested with Kolmogorov-Smirnov test) are presented as 
means ± standard deviation. Comparisons of values between 
two groups were made using t-test or between multiple 
groups using analysis of variance (ANOVA test), with post-
hoc Scheffe testing. Factor covariance was examined using 
analysis of covariance (ANOVA). Statistical significance was 
determined at the level of 0.05. Univariate and multivariate 
logistic regression analysis was employed to determine the 
predicting value of parameters for discrimination between 
the two groups and adjust for differences. Obtained models 
were confirmed by receiver operator characteristic (ROC) 
analysis.
Results
The herein analyzed patient cohort comprised a total of 124 
CAD patients (80.0%) upon acute MI with the ST segment 
elevation (STEMI) and 31 patients (20.0%) with acute 
MI without ST segment elevation (NSTEMI). The most 
common localization of the MI was the anteroseptal wall of 
the left ventricle (61 subjects, 39.4%) and inferoposterior 
localization (61 subjects, 39.4%) while 5 data subjects (3.2%) 
had the lateral localization. 
For further statistical evaluation, patients were 
subdivided into subgroups comprising STEMI patients 
(STEMI CAD group) and NSTEMI patients (NSTEMI 
CAD group). Evaluation of obtained results was also done 
in accordance with the spatial MI presentation, anteroseptal 
MI (ASMI CAD), inferior wall MI and lateral wall MI. No 
statistically relevant differences were observed between the 
STEMI CAD and NSTEMI CAD groups in comparison 
with control for the total vitamin D and 25(OH)D3 serum 
levels (ANOVA, P>0.05, Table S2). Moreover, the measured 
values for total vitamin D in the serum of all groups were 
within the suggested range 50–125 nmol/L (26). Statistically 
higher levels of 25(OH)D2, probably due to unreported 
vitamin D supplementation, were observed in the CAD 
group (t-test, t=2.61, P=0.01) in comparison with control. 
Considering that vitamin D3 biological relevance in 
humans is higher than those of vitamin D2 this result does 
not suggest a direct clinical implication for the CAD in this 
case (27,28). 
Genotyping data showed that the VDBP (rs4588) 
genotype T/T was statistically marginally more prevalent 
(χ2 test: P=0.08) in the CAD group in comparison with 
control (Table S3). No statistically relevant differences were 
observed for the VDBP (rs7041) genotypes between CAD 
and control. Moreover, analysis of allele frequencies and 
genotypes for VDBP (rs4588) and (rs7041) polymorphisms 
in the CAD group in comparison with controls showed 
no statistical relevance (Tables S4,S5). However, when the 
analysis of the VDBP (rs4588) genotype was performed 
according to the clinical presentation of the MI, the VDBP 
(rs4588) T/T genotype was statistically more prevalent 
(P=0.034) in the ASMI CAD group in comparison with 
control (Table 2). Statistical comparison between other 
groups yielded no statistically relevant data. However, in 
the recessive model the T/T genotype for VDBP (rs4588) 
was associated with a 2.94-fold significantly higher risk (95% 
CI: 1.13–7.66, P=0.023) for anteroseptal MI (Table 3). 
Due to significant differences observed between CAD 
and control groups related to the gender, AH diagnosis and 
smoking, additional interaction analyses were performed. 
Significant interactions were found between VDBP (rs4588) 
and gender where male had more prevalently the G/G 
variant while woman had more prevalently the G/T variant 
(Table S6). Moreover, for AH, a significant interaction was 
observed only for AH and the group while AH correlation 
with VDBP (rs4588) was not significant (data not shown). 
At last, smokers were less represented by the VDBP 
(rs4588) G/G variant and more by the VDBP (rs4588) T/T 
variant (Table S7). As smoking is a known CAD risk factor, 
a statistical correlation between the VDBP(rs4588) T/T 
genotype and CAD patients who are smokers compared to 
non-smoking controls was interesting (χ2=8.59, P=0.014 
and recessive model: χ2=7.69, P=0.005; OR =4.51; 95% Cl: 
1.44–14.14) (Table 4) suggesting that VDBP(rs4588) T/T 
genotype may be one of the risk factors for development of 
CAD in smokers.
The VDBP (rs4588)  genotype was analysed in 
comparison with the 25(OH)D2, 25(OH)D3 and total 
vitamin D serum levels in both CAD patients and controls 
(Table 5). Genetic variation in VDBP (rs4588) influences 
25(OH)D serum levels upon vitamin D3 and not vitamin 
D2 supplementation (29) and the herein employed LC-
MS/MS method was therefore used for measurement 
of corresponding 25(OH)D forms and total vitamin D 
levels in the serum (30,31). VDBP (rs4588) genotype 
G/G presence correlated with higher levels of 25(OH)
D2 (ANOVA, P=0.008). Similarly, the VDBP (rs4588) 
genotype G/G presence correlated with higher 25(OH)
D3 levels (ANOVA; P=0.034). At last, the VDBP (rs4588) 
genotype G/G presence correlated with higher levels of 
total vitamin D (ANOVA; P=0.011). Marginal statistical 
correlation for VDBP (rs7041) C/C genotype presence with 
higher levels of total vitamin D was also observed (ANOVA; 
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P=0.035). For 25(OH)D3 and VDBP (rs4588) (analysis of 
covariance, F=4.62, P=0.033) as well as total vitamin D and 
VDBP (rs4588) (analysis of covariance, F=4.70, P=0.031) 
the age was a significant covariate in the CAD group with 
the VDBP (rs4588) G/T genotype where levels of vitamin 
D and age were slightly negatively correlated with 25(OH)
D3 and total vitamin D serum levels. 
Finally, logistic regression analysis was performed to 
analyse blood pressure, smoking and body mass index 
(BMI) confounding on vitamin D levels and VDBP 
(rs4588) genotype in CAD and ASMI CAD groups 
(Table 6). Although vitamin D levels (D2, D3 and total 
D vitamin level) did not show predicting value for both 
CAD and ASMI CAD group discrimination from control, 
Table 2 Analyzed polymorphisms of the vitamin D-binding protein (VDBP) (rs4588) and (rs7041) in coronary artery disease group with 
anteroseptal myocardial infarction (ASMI CAD) in comparison with control 
Genotype
ASMI CAD Control
P value
N % N %
VDBP (rs4588)
G/G 31 50.8 50 48.1 0.034*
G/T 18 29.5 46 44.2
T/T 12 19.7 8 7.7
Total 61 100.0 104 100.0 –
VDBP (rs7041)
A/A 13 21.3 24 23.1 0.950
A/C 26 42.6 42 40.4
C/C 22 36.1 38 36.5
Total 61 100.0 104 100.0 –
Statistical significance (χ2 test, P<0.05) is denoted with an asterisk (*). N, number of subjects; ASMI, anteroseptal myocardial infarction; 
CAD, coronary artery disease.
Table 3 Inheritance models for VDBP (rs4588) polymorphism in ASMI CAD and control groups
VDBP (rs4588) model Genotype ASMI CAD (N=61), n (%) Controls (N=104), n (%) P value OR (95% CI)
Codominant G/G 31 (50.8) 50 (48.1) – 1.00
G/T 18 (29.5) 46 (44.2) 0.199 0.63 (0.31–1.28)
T/T 12 (19.7) 8 (7.7) 0.078 2.42 (0.89–6.18)
Dominant G/G 31 (50.8) 50 (48.1) 0.729 1.00
G/T-T/T 30 (49.2) 54 (51.9) 0.90 (0.48–1.69)
Recessive G/G-G/T 49 (80.3) 96 (92.3) 0.023* 1.00
T/T 12 (19.7) 8 (7.7) 2.94 (1.13–7.66)*
Over dominant G/G-T/T 43 (70.5) 58 (55.8) 0.061 1.00
G/T 18 (29.5) 46 (44.2) 0.53 (0.27–1.03)
Additive G/G 31 (42.5) 50 (44.6) 0.764 1.00
2T/T-G/T 42 (57.5) 62 (55.4) 1.09 (0.60–1.98)
Statistical relevance (χ2 test, P<0.05) is denoted with an asterisk (*). N, number of subjects; ASMI, anteroseptal myocardial infarction; CAD, 
coronary artery disease; VDBP, vitamin D-binding protein; OR, odds ratio; CI, confidence interval.
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the multivariate logistic regression modelling enabled 
association of total vitamin D level and VDBP (rs4588 
T/T genotype with CAD and ASMI CAD occurrence 
(Table 6). Logistic regression (adjusted for BMI, smoking 
and systolic pressure), showed lower levels of total vitamin 
D with VDBP (rs4588) T/T genotype discriminate CAD 
from healthy individuals [model P=0.046, R2 =0.057, ROC 
area under the curve (AUC) =0.624, P=0.037]. The same 
goes for ASMI CAD distinction from control group (model 
P=0.037, R2 =0.047, ROC AUC =0.625, P=0.034).
Discussion
Vitamin D plays a pivotal role in the organism and it 
regulates the function of 3% of the human genome (32). 
Although 1,25(OH)D is the active form of this vitamin, 
the serum quantity of 25(OH)D is clinically relevant (33). 
Recent studies brought scientific evidence on connection 
Table 4 Genotype frequency of VDBP (rs4588) polymorphism in coronary artery disease CAD smokers group in comparison with non-smoking 
controls 
Genotype
CAD smoking Control non-smoking
OR (95% CI) P value
N % N %
VDBP (rs4588) –
G/G 40 46.5 39 47 0.014*
G/T 30 34.9 40 48.2
T/T 16 18.6 4 4.8
Total 86 100.0 83 100.0 –
Model
Recessive 0.005*
G/G-G/T 70 81.4 79 95.2 1.00
T/T 16 18.6 4 4.8 4.51 (1.44–14.14)*
Statistical relevance (χ2 test, P<0.05) is denoted with an asterisk (*). N, number of subjects. VDBP, vitamin D-binding protein; CAD, 
coronary artery disease; OR, odds ratio; CI, confidence interval.
Table 5 Analysis of 25-hydroxyvitamin D2 [25(OH)D2], 25-hydroxyvitamin D3 [25(OH)D3] and total vitamin D serum levels for different VDBP 
(rs4588) and VDBP (rs7041) genotypes 
Genotype N 25(OH)D2 25(OH)D3 Total vitamin D
VDBP (rs4588)
G/G 100 3.18±3.91 61.52±28.86 64.71±28.87
G/T 67 1.67±2.89 50.65±24.87 52.32±24.30
T/T 21 1.39±2.76 52.29±27.92 53.67±27.45
P value 188 0.008* 0.034* 0.011*
VDBP (rs7041)
A/A 39 1.69±3.03 47.96±24.98 49.65±24.69
A/C 78 2.39±3.55 57.03±27.37 59.42±26.66
C/C 71 2.92±3.73 60.92±28.89 63.83±29.38
P value 188 0.213 0.063 0.035*
Results are presented as mean values in nmol/L ± standard deviation (SD). Statistical significance (ANOVA P<0.05) is denoted with an 
asterisk (*). N, number of subjects; VDBP, vitamin D-binding protein.
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of 25(OH)D serum levels with beneficial effects on 
fibrinolysis, lipid profile, thrombogenicity, regeneration of 
the endothelium and smooth muscle cell growth (34) but 
also with hypertension and metabolic syndrome (35). Also, 
low values of circulating 25(OH)D are associated with an 
increased risk of CVD as well and with the corresponding 
mortality (14,36). In the herein presented study, the 
levels of total vitamin D in the serum were normal in 
all tested subjects which was partially expected as in the 
geographical area (Primorsko-Goranska County) where 
the tested subjects were recruited, the number of sunny 
days is abundant and the population has a wider approach 
to the Mediterranean type of diet. However, the levels of 
25(OH)D in the serum of tested subjects were statistically 
significantly different according to the VDBP genotype 
which is expected as more than 85% of 25(OH)D in 
the serum is bound to VDBP (37). The herein analyzed 
VDBP polymorphisms (rs4588) and (rs7041) account for 
about 80% of the variability in 25(OH)D serum levels 
(22,38) and the VDBP (rs4588) genotype G/G presence 
correlated with higher levels of 25(OH)D2, higher levels 
of 25(OH)D3 and higher levels of total vitamin D in the 
serum. Observed genotype-phenotype correlations were 
not associated with MI. However, VDBP (rs4588) T/T 
genotype was statistically marginally more prevalent (χ2 test: 
P=0.08) in the MI CAD group in comparison with control. 
Interestingly, although D2, D3 and total D vitamin levels 
did not show predicting value for both CAD and ASMI 
CAD group discrimination from control, the multivariate 
logistic regression modelling enabled association of total 
vitamin D level and VDBP (rs4588) T/T genotype with 
CAD and ASMI CAD occurrence and lower levels of total 
vitamin D with VDBP (rs4588) T/T genotype discriminate 
CAD from healthy individuals. The same goes for ASMI 
CAD distinction from control group. This result should 
be further studied on a larger cohort to derive conclusive 
results. Indeed, Stakisaitis et al. (38) showed a correlation of 
VDBP polymorphism (rs7041) C allele with increased risk 
of CAD. In another study on an Iranian cohort, a significant 
association of VDBP (rs7041) G/G genotype and VDBP 
(rs4588) C/A genotype and allele A with CAD has been 
also found (25). These data are not in concordance with a 
large Atherosclerosis Risk in Communities (ARIC) study 
were no impact of the VDBP polymorphisms on CAD 
was observed either for black or white population (20). 
Similarly, Daffara et al. (23) studied a large cohort of CAD 
patients undergoing coronary angiography and established 
no correlation of the VDBP (rs4588) and (rs7041) 
polymorphisms with CAD. Interestingly, in all above 
mentioned studies the levels of 25(OH)D were assessed 
as deficiency in majority of tested subjects. As 25(OH)D 
levels in our study were normal, we analyzed the VDBP 
Table 6 Multivariate logistic regression results on predictors of CAD and ASMI CAD 
Variable
Group discrimination
CAD/control ASMI CAD/control
beta SE (beta) P value beta SE (beta) P value
Age 0.093 0.014 0.001 0.090 0.018 0.001
BMI 0.091 0.035 0.009 0.035 0.039 0.381
Systolic pressure −0.020 0.008 0.013 −0.021 0.011 0.042
Serum levels 
25(OH)D2 0.077 0.088 0.379 0.065 0,095 0.427
25(OH)D3 −0.009 0.005 0.119 −0.005 0.006 0.383
Total vitamin D −0.007 0.005 0.213 −0.003 0.006 0.569
Variable set
Total vitamin D −0.011 0.006 0.048 −0.006 0.007 0.387
VDBP rs4588 (T/T) 0.076 0.331 0.021 0.083 0.067 0.023
25(OH)D2, 25-hydroxyvitamin D2; 25(OH)D3, 25-hydroxyvitamin D3; VDBP, vitamin D-binding protein; ASMI, anteroseptal myocardial 
infarction; CAD, coronary artery disease; BMI, body mass index; SE, standard error.
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(rs4588) genotype according to the clinical presentation of 
the MI. The VDBP (rs4588) T/T genotype was statistically 
more prevalent (χ2 test: P=0.034) in the ASMI CAD group 
in comparison with control. Nevertheless, VDBP (rs4588) 
T/T genotype showed to be generally more prevalent in 
smokers, and ASMI CAD were also more prevalent in 
smokers. Moreover, T/T genotype was overrepresented 
in smoking CAD patients’ cohort in comparison with 
non-smoking controls. Even though frequencies of alleles 
between ASMI CAD group and control for VDBP (rs4588) 
were not statistically relevant, in the recessive model the T/
T genotype for VDBP (rs4588) was found to be associated 
with a 2.94-fold significantly higher risk (95% CI: 1.13–
7.66, P=0.023) for the anteroseptal MI. While it has been 
speculated that vitamin D deficiency may be correlated with 
acute MI (39)] and our study provided n evidence for this 
assumption, a role of T/T VDBP (rs4588) genotype has not 
been previously described for this specific group of patients. 
It should be emphasized that the major limitation of the 
presented study may be in a rather small number of the 
samples. Still, the power calculated according to the allele 
frequency in the general population, hypothetical frequency 
of the CAD with the error level type I as 0.05 and power 
of analysis 80%, showed that the minimal sample size for 
rs4588 is 132 patients and for rs731236 116 patients, which 
is met in the presented study. Observed differences in the 
gender, AH and smoking may add bias to the results as well.
In conclusion, obtained data speak in favor to the 
VDBP (rs4588) T/T genotype as a susceptibility factor for 
anteroseptal MI where the same genotype showed to be 
generally more prevalent in smokers, and anteroseptal MI 
was also more prevalent in smokers. Larger prospective 
studies should be conducted to better elucidate the 
association of this specific VDBP genotype in correlation 
with smoking as susceptibility factor for anteroseptal MI.
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Supplementary
Supplementary file 1
Subjects and procedures used for clinical evaluation of 
patients
A total of 124 patients (80.0%) had acute myocardial 
infarction with the ST segment elevation (STEMI), while 
31 patients (20.0%) had acute myocardial infarction 
without STEMI (NSTEMI). Ninety-four (60.6%) of the 
data subjects had been subjected to percutaneous coronary 
intervention on the anterior descending branch of the left 
coronary artery. Percutaneous coronary intervention on 
the circumflexed branch of the left coronary artery was 
performed in 25 data subjects (16.1%), while in 43 data 
subjects (27.7%) it was performed on the right coronary 
artery. One hundred and seventeen patients (75.5%) of 
the CAD group have suffered from arterial hypertension 
(AH), 122 CAD subjects (78.7%) have suffered from 
hyperlipoproteinemia, 29 CAD subjects (18.7%) have 
suffered from diabetes, 5 CAD subjects (3.2%) have suffered 
from chronic obstructive pulmonary disease (COPD). A 
total number of 86 data subjects (55.5%) were smokers and 
93 CAD subjects (60.0%) had a positive family history of 
cardiovascular diseases.
A statistically significant difference between CAD 
and control group was observed in gender distribution 
(81.9% male in CAD group vs. 65.4% male in control 
group). Statistically significant difference was also observed 
between CAD and control group in age distribution (58 vs. 
47 years, P<0.001). There was also a difference in the body 
mass index (28.5 vs. 27.2 kg/m2, P=0.017) without clinical 
significance as both values were in the overweight range. 
While predisposing factors including hyperlipoproteinemia, 
COPD prevalence and posit ive family history of 
cardiovascular diseases showed no differences between 
groups, statistically significant difference between groups 
was observed in prevalence of AH (75.5% vs. 38.5%, 
P<0.001), diabetes mellitus (18.7% vs. 8.7%, P=0.025) and 
smoking (55.5% vs. 21.2%, P<0.001) (Table S1).
Blood samples of the affected subjects were taken 
between 7 and 8 am, the second day after the admission 
to rehabilitation treatment. Serum levels of vitamin D 
{25-hydroxyvitamin D [25(OH)D]} were determined by 
the mass spectrometry (Xevo TQ-S, Waters corporation, 
Milford USA), natriuretic peptide (BNP), high sensitive 
C-reactive protein (HsCRP) and other routine laboratory 
findings [complete blood count (CBC), plasma glucose 
levels, urea, creatinine, sodium, potassium, calcium 
aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), gamma-glutamyl transferase (GGT), alkaline 
phosphatase (ALP); bilirubin, cholesterol, triglycerides, 
high-density lipoprotein (HDL), low-density lipoprotein 
(LDL), thyroid-stimulating hormone (TSH)]. Erythrocyte 
sedimentation was defined by Westergreen method (Becton 
Dickinson, Franklin Lakes, NJ, USA). Haemoglobin was 
defined via “Sulfolyser oxidizing method”, erythrocytes 
and hematocrit via “Hydro Dynamic Focusing method” on 
haematological analyzer (Haematology analyser XS-1000i, 
Sysmex, Kobe, Japan). Leukocytes, neutrophils, eosinophils, 
basophils, lymphocytes and monocytes were determined by 
the flow cytometry with the help of/means semiconductor 
laser on a hematologic analyzer (Haematology analyser XS-
1000i, Sysmex, Kobe, Japan). Mean cell volume (MCV), 
mean cell hemoglobin (MCH) and mean corpuscular 
hemoglobin concentration (MCHC) were calculated on the 
bases of the data obtained on the hematological analyzer. 
Bilirubin, AST, ALT, glutamyl transferase (GT), Na+, K+, 
urea, creatinine, high sensitivity C-reactive protein (hsCRP), 
cholesterol, triglycerides, HDL, LDL, TSH and urates 
were determined by photometric method using Dimension 
Xpand [Siemens Healthcare Diagnostics, Newark (DE), 
USA]. All the laboratory parameters were determined in the 
laboratory of Specialized hospital for cardiac, pulmonary 
and rheumatic diseases “Thalassotherapia Opatija”. During 
this research, the following anthropometric measurements 
were taken (all by using the same devices): height in 
meters (m), weight in kilograms (kg) by using manual scale. 
Systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) were measured in persons while sitting, after taking 
a rest for at least 15 minutes. Body mass index (BMI) is 
calculated as weight (kg)/height (m2). Ergospirometry 
testing was performed on a bicycle ergometer with a 
gradual increase in load (Cortex Metamax) and it included 
the following phases: start load of 50 watt in duration of 3 
minutes up to 60 cycles per minute, every 3-minute increase 
of load for 25 watts. The criteria for achieving maximum 
capacity were one or more of the following: Achieving 
Plato VO2, maximum heart frequency greater than 90% of 
the anticipated values for that age (220 years), respiratory 
exchange ratio (RER) more than 1/15 (although RER values 
are not indicatively accurate for the maximum capacity). 
The data are automatically processed by using the standard 
formula (based on the reference values) and are presented 
as descriptive data. The measured variables include: 
VO2 (L/min), VCO2 (L/min), VO2/kg (mL/min/kg), load 
(W/min), heart rate (HR) (b/min), heart rate recovery 
(HRR) (b/min) (L/min), EQO2, EQCO2, minute ventilation 
(VE) (L/min), breathing rate (BR) (%), blood flow 
(BF) (L/min). All echocardiograph image acquisitions 
were done for all the participants at the beginning of the 
rehabilitation process. The tests were conducted by the 
examiner having 8 years of experience, who was unfamiliar 
with the study protocol and characteristics of the patients. 
Echocardiograph data were obtained via ultrasound 
device of the Vivid E9 system (GE Vingmed Ultrasound 
AS, Horten,  Norway) equipped with a s ingle 2D 
3.5-MHz transducer (M5S-D), one 3D 3.5-MHz transducer 
(4C-D)—analytical software for monitoring peaks and 1 
workstation for background processing (EchoPAC BT 
11.1.0, GE Medical System, Horten, Norway). All subjects 
were connected to the electrocardiogram (ECG) and viewed 
in their left-hand side position. First the conventional 
echocardiography was performed for the purpose of the 
observation of cardiac structures from parasternal long 
and short axes and apical display of 4 chambers. Early and 
late peak diastolic flow rates (E-wave and A-wave) were 
measured and then the E/A proportion were calculated. 
Then the 3D transducer was used to obtain a clear LV 
endocardium image with the apical 4-chamber view in 4D 
mode. Patients were asked to keep their breath at the end. 
Imaging allows a sector with depths of 30° and a width of 
100° in real time. 3D dynamic left ventricular (LV) images 
in the acquisition of full volume are collected and stored. 
The frame rate of the volumetric image was 25 to 35 frames 
per second. After the software has identified the borders 
of endocardial and epicardial lines for the entire 3D data 
set, the left ventricular model, left ventricular end-diastolic 
volume (LVEDV), left ventricular end systolic volume 
(LVESV), cardiac output (CO), stroke volume (SV), and the 
left ventricle ejection fraction (LVEF) are generated. 
Solid phase extraction (SPE) procedure and liquid 
chromatography, tandem mass spectrometry (LC-MS/MS)
For SPE, methanol and water (Honeywell, Morris Plains, 
New Jersey, USA) were used for preparation of working 
solutions as follows: 80% methanol/20% isopropyl alcohol 
(IPA) (v/v) (Sigma-Aldrich, St. Louis, Missouri, USA), 60% 
methanol (aq.), 5% methanol (aq.), 95% methanol/5% IPA 
(v/v). Zinc sulfate (0.2 M), 2 mM ammonium acetate/0.1% 
formic acid (v/v) (aq.), 2 mM ammonium acetate/0.1% 
formic acid (v/v) in methanol were purchased from (Sigma-
Aldrich, St. Louis, Missouri, USA). Briefly, for SPE 
20 µL of internal standard mix was added into 150 µL 
plasma samples aliquots and vortexed briefly. One hundred 
and fifty µL of zinc sulphate (0.2 M) was added to the 
samples followed by addition of 600 µL of 100% methanol. 
Samples were then centrifuged 10 minutes at 14,000 rpm. 
After SPE, supernatant containing 25(OH)D2 and 25(OH)
D3 was obtained and collected for each sample. Samples 
were additionally eluted by use of OASIS® HLB µElution 
plate 30 µm (Waters, Milford, Massachusetts, USA) for 
the final protein clean-up. Calibrator mix 25(OH)D3 and 
25(OH)D2 solutions (Sigma-Aldrich, St. Louis, Missouri, 
USA) of known concentrations were used to assess the 
linearity of the measurement. Quality control (QC) mix of 
25(OH)D3 and 25(OH)D2 solutions ClinChek® (LGC, 
Teddington, UK) were used as measurement quality 
assurance. Internal standard (250 ng/mL) was the referent 
solution of vitamin D2 (triply deuterated) and D3 (doubly 
deuterated) (Waters, Milford, Massachusetts, USA), these 
were added to each sample, QCs and calibrators, relative 
to which all 25(OH)D2 and 25(OH)D3 and concentrations 
were measured (internal control is to account for possible 
sample loss during preparation). UPLC settings included 
BEH-phenyl column (2.1×50 mm, 1.7 µm) (Waters, 
Milford, Massachusetts, USA), used to separate the OH 
vitamins D from lipids, mobile phase A containing 2 mM 
ammonium acetate in 0.1% formic acid (aq.), mobile phase 
B consisted of 2 mM ammonium acetate in 0.1% formic 
acid (in methanol), gradient elution (0.45 mL/min flow, 
4.2 min run time, 10 µL injection volume, 45 ℃ column 
temperature, 10 ℃ sample temperature, weak wash solution 
containing 60%/40% (v/v) methanol/water and strong 
wash solution containing 100% methanol). The mass 
spectrometer settings were set on electrospray ionization 
positive mode, 1.5 kV capillary voltage, 450 ℃ desolvation 
temperature, 1,100 L/h desolvation gas flow, 150 L/h cone 
gas, 150 ℃ source temperature, 5.0 µL/min sample flow and 
multiple reaction monitoring acquisition mode (MRM).
Table S3 Analyzed polymorphisms (rs4588) and (rs7041) of the vitamin D-binding protein (VDBP) in coronary artery disease CAD group in 
comparison with control 
Genotype
CAD Control
P (χ2 test)
N % N %
VDBP (rs4588)
G/G 83 53.5 50 48.1 0.080
G/T 50 32.3 46 44.2
T/T 22 14.2 8 7.7
Total 155 100.0 104 100.0 –
VDBP (rs7041)
A/A 30 19.4 24 23.1 0.643
A/C 71 45.8 42 40.4
C/C 54 34.8 38 36.5
Total 155 100.0 104 100.0 –
No statistical significance (χ2 test, P<0.05) was observed. N, number of subjects; VDBP, vitamin D-binding protein; CAD, coronary artery 
disease.
Table S2 Serum levels of 25 hydroxyvitamin D2 [25(OH)D2], 25 hydroxyvitamin D3 [25(OH)D3] and total vitamin D in ST-segment elevation 
myocardial infarction (STEMI) coronary artery disease (CAD), non-ST-segment elevation myocardial infarction (NSTEMI) CAD and control 
groups 
Serum levels CAD STEMI (N=96) CAD NSTEMI (N=22) Control (N=70) P value
25(OH)D2 3.20±3.78 1.89±3.34 1.58±3.02 0.010*
25(OH)D3 55.51±29.48 48.25±24.85 60.76±25.73 0.157
Total vitamin D 58.71±29.40 50.15±24.48 62.34±25.88 0.195
Results are presented as mean values in nmol/L ± standard deviation (SD). Statistical significance (ANOVA, P<0.05) is denoted with an 
asterisk (*). N, number of subjects.
Table S1 Risk factors prevalence in coronary artery disease (CAD) patients and control group 
Risk factors
CAD (n=155) Control (n=104)
P value
N % N %
Arterial hypertension diagnosis (AH)** 117 75.5 40 38.5 <0.001*
Hyperlipoproteinemia 122 78.7 78 75.0 0.485
Diabetes mellitus 29 18.7 9 8.7 0.025*
COPD 5 3.2 0 0.0 0.085*
Smoking 86 55.5 22 21.2 <0.001*
Positive family history 93 60.0 61 58.7 0.829
*, Fisher exact test; **, the patients within the CAD group have a medical history with the diagnosis of arterial hypertension and are under 
prescribed antihypertensive therapy. Statistical significance (χ2 test) is denoted with an asterisk (*). N, number of subjects; COPD, chronic 
obstructive pulmonary disease.
Table S5 Allele frequency of VDBP rs4588 and rs7041 polymorphisms in coronary artery disease group with anteroseptal myocardial infarction 
(ASMI CAD) in comparison with controls. No statistically relevant differences were observed
SNP/group Allele G (%) Allele T (%) Allele C (%) Allele A (%) Total P value
OR (CI lower–CI 
upper)
VDBP (rs4588) 0.383 1.24 (0.77–1.99)
ASMI CAD 80 [66] 42 [34] – – 122
Controls 146 [70] 62 [30] – – 208
VDBP (rs7041) 0.920 0.97 (0.62–1.53)
ASMI CAD – – 70 [57] 52 [43] 122
Controls – – 118 [57]  90 [43] 208
VDBP, vitamin D-binding protein; ASMI, anteroseptal myocardial infarction; CAD, coronary artery disease; OR, odds ratio; CI, confidence 
interval.
Table S6 Contingency table for the genetic polymorphisms VDBP (rs4588) association with gender 
VDBP (rs4588)
Male Female
P value
N % N %
G/G 107 54.9 26 40.6 0.021*
G/T 63 32.3 33 51.6
T/T 25 12.8 5 7.8
Total 195 100.0 64 100.0 –
Statistical relevance (χ2 test, P<0.05) is denoted with an asterisk (*). N, number of subjects; VDBP, vitamin D-binding protein.
Table S7 Contingency table for the genetic polymorphisms VDBP (rs4588) association with smoking
VDBP (rs4588)
Smoking Non-smoking
P value
N % N %
G/G 49 45.4 84 55.6 <0.001
G/T 37 34.3 59 39.1
T/T 22 20.4 8 5.3
Total 108 100.0 151 100.0 –
Statistical relevance (χ2 test, P<0.05) is denoted with an asterisk (*). N, number of subjects; VDBP, vitamin D-binding protein.
Table S4 Allele frequency of VDBP rs4588 polymorphism and VDBP rs7041 polymorphism in coronary artery disease CAD group in 
comparison with controls. No statistically relevant differences were observed
SNP/group Allele G (%) Allele T (%) Allele C (%) Allele A (%) Total P (χ2 test)
OR (CI lower–CI 
upper)
VDBP (rs4588) 0.888 1.02 (0.70–1.50)
CAD 216 [70] 94 [30] – – 310
Controls 146 [70] 62 [30] – – 208
VDBP (rs7041) 0.823 0.96 (0.67–1.37)
CAD – – 179 [58] 131 [42] 310
Controls – – 118 [57] 90 [43] 208
VDBP, vitamin D-binding protein; CAD, coronary artery disease; OR, odds ratio; CI, confidence interval.
